Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 4.580
-0.010 (-0.22%)
At close: Mar 2, 2026
Egetis Therapeutics AB Revenue
In the year 2025, Egetis Therapeutics AB had annual revenue of 62.40M SEK with 35.36% growth. Egetis Therapeutics AB had revenue of 17.90M in the quarter ending December 31, 2025, with 65.74% growth.
Revenue
62.40M
Revenue Growth
+35.36%
P/S Ratio
29.07
Revenue / Employee
1.56M
Employees
40
Market Cap
1.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.40M | 16.30M | 35.36% |
| Dec 31, 2024 | 46.10M | -11.50M | -19.97% |
| Dec 31, 2023 | 57.60M | 35.00M | 154.87% |
| Dec 31, 2022 | 22.60M | -15.60M | -40.84% |
| Dec 31, 2021 | 38.20M | -2.46M | -6.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 434.40M |
| Cantargia AB | 316.70M |
| BioInvent International AB | 226.50M |
| Hansa Biopharma AB | 222.27M |
| Genovis AB (publ.) | 129.65M |
| Vicore Pharma Holding AB | 8.50M |
| Medivir AB | 8.50M |
| Xspray Pharma AB | 6.43M |